Ben Langston1, Jo Armes, Anneliese Levy, Elizabeth Tidey, Emma Ream. 1. King's College London, Kings Health Partners, Florence Nightingale School of Nursing and Midwifery, Waterloo Campus, James Clerk Maxwell Building, 57 Waterloo Road, London, SE1 8WA, UK.
Abstract
BACKGROUND: Cancer-related fatigue is a significant clinical problem and is a symptom commonly experienced by patients with differing cancer types during and following treatment. It is a distressing symptom which interferes with functioning in daily life. However, much less is known about the prevalence and severity of fatigue in prostate cancer when compared to other cancer types, such as breast cancer. METHODS: A systematic review was conducted to appraise the prevalence and severity of cancer-related fatigue in prostate cancer. Systematic searches of published quantitative research relating to the prevalence and severity of fatigue were conducted using databases, including Medline, PsychINFO, CINAHL and ISI Web of Knowledge (January 2012). Included papers measured the prevalence or severity of prostate-cancer-related fatigue and differentiated fatigue outcomes (prevalence, severity) between treatment modalities. RESULTS: Nineteen studies were eligible for the review, of which 17 were cross-sectional and 2 longitudinal. Findings suggest that the prevalence of any fatigue is as high as 74%, whilst chronic fatigue prevalence was highest (39%) when hormone therapy was combined with radiotherapy. Fatigue severity is reported as worse in hormone therapy and treatment combining hormone therapy and radiotherapy. CONCLUSIONS: Fatigue is a common symptom for men with prostate cancer, particularly those prescribed hormone therapy. A wide variety of tools were used to measure fatigue prevalence and severity, which made comparisons across studies difficult. The review is limited by methodological shortcomings in the studies included.
BACKGROUND:Cancer-related fatigue is a significant clinical problem and is a symptom commonly experienced by patients with differing cancer types during and following treatment. It is a distressing symptom which interferes with functioning in daily life. However, much less is known about the prevalence and severity of fatigue in prostate cancer when compared to other cancer types, such as breast cancer. METHODS: A systematic review was conducted to appraise the prevalence and severity of cancer-related fatigue in prostate cancer. Systematic searches of published quantitative research relating to the prevalence and severity of fatigue were conducted using databases, including Medline, PsychINFO, CINAHL and ISI Web of Knowledge (January 2012). Included papers measured the prevalence or severity of prostate-cancer-related fatigue and differentiated fatigue outcomes (prevalence, severity) between treatment modalities. RESULTS: Nineteen studies were eligible for the review, of which 17 were cross-sectional and 2 longitudinal. Findings suggest that the prevalence of any fatigue is as high as 74%, whilst chronic fatigue prevalence was highest (39%) when hormone therapy was combined with radiotherapy. Fatigue severity is reported as worse in hormone therapy and treatment combining hormone therapy and radiotherapy. CONCLUSIONS:Fatigue is a common symptom for men with prostate cancer, particularly those prescribed hormone therapy. A wide variety of tools were used to measure fatigue prevalence and severity, which made comparisons across studies difficult. The review is limited by methodological shortcomings in the studies included.
Authors: Jennifer A Ligibel; Ann Partridge; Anita Giobbie-Hurder; Nancy Campbell; Laura Shockro; Taylor Salinardi; Taylor Salinardri; Eric P Winer Journal: J Womens Health (Larchmt) Date: 2010-08 Impact factor: 2.681
Authors: Terry A Badger; Chris Segrin; Aurelio J Figueredo; Joanne Harrington; Kate Sheppard; Stacey Passalacqua; Alice Pasvogel; Maria Bishop Journal: Qual Life Res Date: 2010-12-19 Impact factor: 4.147
Authors: D J Storey; D B McLaren; M A Atkinson; I Butcher; S Liggatt; R O'Dea; J F Smyth; M Sharpe Journal: Ann Oncol Date: 2011-03-24 Impact factor: 32.976
Authors: Velda J Gonzalez; Jason Beckstead; Maureen Groer; Susan McMillan; Desiree Ortiz; Sara Marrero; Leorey N Saligan Journal: P R Health Sci J Date: 2019-06 Impact factor: 0.705
Authors: Dominic Pilon; Ajay S Behl; Lorie A Ellis; Marie-Noëlle Robitaille; Patrick Lefebvre; Nancy A Dawson Journal: Am Health Drug Benefits Date: 2017-05
Authors: Velda J Gonzalez; Leorey N Saligan; Brooke L Fridley; Humberto Ortiz-Zuazaga; Lauren S Aaronson Journal: P R Health Sci J Date: 2017-12 Impact factor: 0.705
Authors: Sigrun Dahl; Jon Håvard Loge; Viktor Berge; Alv Andreas Dahl; Milada Cvancarova; Sophie Dorothea Fosså Journal: J Cancer Surviv Date: 2014-09-13 Impact factor: 4.442